MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
 
 
 
Chirurgie / Research Laboratories / Forschung / Groups and Subgroups / Starlinger / Publications
 

ARGE Starlinger Publications

Original Articles
  • Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity.

     Pereyra D, Offensperger F, Klinglmueller F, Haegele S, Oehlberger L, Gruenberger T, Brostjan C, Starlinger P.

     PLoS One. 2017 Apr 13;12(4):e0175359. doi: 10.1371/journal.pone.0175359. eCollection 2017.
  • The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.

     Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L, Strobel B, Schubert TL, Riedl F, Mitteregger D, Burnet M, Starlinger P, Oberhuber G, Deuschle U, Rohr-Udilova N, Podesser BK, Peck-Radosavljevic M, Reiberger T, Kremoser C, Trauner M.

     J Hepatol. 2017 Apr;66(4):724-733. doi: 10.1016/j.jhep.2016.12.005. Epub 2016 Dec 18.
  •  Perioperative Non-Invasive Indocyanine Green-Clearance Testing to Predict Postoperative Outcome after Liver Resection.

     Haegele S, Reiter S, Wanek D, Offensperger F, Pereyra D, Stremitzer S, Fleischmann E, Brostjan C, Gruenberger T, Starlinger P.

     PLoS One. 2016 Nov 3;11(11):e0165481. doi: 10.1371/journal.pone.0165481. eCollection 2016.
  • The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance.

     Alidzanovic L, Starlinger P, Schauer D, Maier T, Feldman A, Buchberger E, Stift J, Koeck U, Pop L, Gruenberger B, Gruenberger T, Brostjan C.

     Oncotarget. 2016 Aug 30;7(35):57197-57212. doi: 10.18632/oncotarget.11084.

  • Chemotherapy of colorectal liver metastases induces a rapid rise in intermediate blood monocytes which predicts treatment response.

     Schauer D, Starlinger P, Alidzanovic L, Zajc P, Maier T, Feldman A, Padickakudy R, Buchberger E, Elleder V, Spittler A, Stift J, Pop L, Gruenberger B, Gruenberger T, Brostjan C.

     Oncoimmunology. 2016 Mar 22;5(6):e1160185. doi: 10.1080/2162402X.2016.1160185. eCollection 2016 Jun.
  • Starlinger P, Assinger A. Importance of platelet-derived growth factors in liver regeneration. Expert Rev Gastroenterol Hepatol. 2016 Mar 16:1-3. [Epub ahead of print]
  • Kudira R, Malinka T, Kohler A, Dosch M, Gomez de Agüero M, Melin N, Haegele S, Starlinger P, Maharjan N, Saxena S, Keogh A, Stroka D, Candinas D, Beldi G. P2X1 regulated IL-22 secretion by innate lymphoid cells is required for efficient liver regeneration. Hepatology. 2016 Feb 8. doi: 10.1002/hep.28492.
  • Starlinger P, Assinger A. Defective intra-platelet vascular endothelial growth factor release is associated with liver dysfunction following partial hepatectomy. Hepatology. 2016 Jan 22. doi: 10.1002/hep.28464. [Epub ahead of print]
  • P. Starlinger, S. Haegele, F. Offensperger, L. Oehlberger, D. Pereyra, J. B. Kral, W. C. Schrottmaier, S. Badrnya, T. Reiberger, A. Ferlitsch, J. Stift, F. Luf, C. Brostjan, T. Gruenberger, and A. Assinger. 2015. The Profile of Platelet alpha-Granule Released Molecules Affects Postoperative Liver Regeneration. Hepatology
  • Stremitzer, S., J. Stift, J. Singh, P. Starlinger, B. Gruenberger, D. Tamandl, and T. Gruenberger. 2015. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
  • Stremitzer, S., J. Stift, A. Graf, J. Singh, P. Starlinger, B. Gruenberger, D. Tamandl, and T. Gruenberger. 2015. CEA Change After Neoadjuvant Chemotherapy Including Bevacizumab and Clinical Outcome in Patients Undergoing Liver Resection for Colorectal Liver Metastases. Annals of surgical oncology 22: 1315-1323.
  • Starlinger, P., S. Haegele, D. Wanek, S. Zikeli, D. Schauer, L. Alidzanovic, E. Fleischmann, B. Gruenberger, T. Gruenberger, and C. Brostjan. 2015. Plasma thrombospondin 1 as a predictor of postoperative liver dysfunction. The British journal of surgery.
  • Schweiger, T., C. Nikolowsky, P. Starlinger, D. Traxler, M. Zimmermann, P. Birner, B. Hegedus, B. Dome, M. Bergmann, M. Mildner, W. Klepetko, K. Hoetzenecker, and H. J. Ankersmit. 2015. Stromal expression of heat-shock protein 27 is associated with worse clinical outcome in patients with colorectal cancer lung metastases. PloS one 10: e0120724.
  • Pilat, N., T. Grunberger, F. Langle, M. Mittlbock, B. Perisanidis, S. Kappel, B. Wolf, P. Starlinger, I. Kuhrer, F. Muhlbacher, and D. Kandioler. 2015. Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: A p53 Research Group study. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
  • Ilhan-Mutlu, A., P. Starlinger, T. Perkmann, S. F. Schoppmann, M. Preusser, and P. Birner. 2015. Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer. Biomarkers in medicine 9: 327-335.
  • Haegele, S., F. Offensperger, D. Pereyra, E. Lahner, A. Assinger, E. Fleischmann, B. Gruenberger, T. Gruenberger, C. Brostjan, and P. Starlinger. 2015. Deficiency in Thrombopoietin Induction after Liver Surgery Is Associated with Postoperative Liver Dysfunction. PloS one 10: e0116985.
  • Starlinger, P., M. Lesurtel, C. Brostjan, P. A. Clavien, and T. Gruenberger. 2014. Reply. Hepatology (Baltimore, Md.).
  • Starlinger, P., and T. Gruenberger. 2014. Role of platelets in systemic tissue protection after remote ischemic preconditioning. Hepatology (Baltimore, Md.) 60: 1136-1138.
  • Starlinger, P., C. Brostjan, and T. Gruenberger. 2014. Evidence for serotonin as an inducer of liver regeneration in humans - further investigations. Hepatology (Baltimore, Md.).
  • Starlinger, P., A. Assinger, S. Haegele, D. Wanek, S. Zikeli, D. Schauer, P. Birner, E. Fleischmann, B. Gruenberger, C. Brostjan, and T. Gruenberger. 2014. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology (Baltimore, Md.) 60: 257-266.
  • Schauer, D., P. Starlinger, P. Zajc, L. Alidzanovic, T. Maier, E. Buchberger, L. Pop, B. Gruenberger, T. Gruenberger, and C. Brostjan. 2014. Monocytes with angiogenic potential are selectively induced by liver resection and accumulate near the site of liver regeneration. BMC immunology 15: 50.
  • Reichl, P., M. Fang, P. Starlinger, K. Staufer, R. Nenutil, P. Muller, K. Greplova, D. Valik, S. Dooley, C. Brostjan, T. Gruenberger, J. Shen, K. Man, M. Trauner, J. Yu, C. F. Gao, and W. Mikulits. 2014. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. International journal of cancer. Journal international du cancer.
  • Starlinger, P., D. Schauer, L. Alidzanovic, S. Zikeli, K. Gebhardt, F. Luf, E. Fleischmann, B. Perisanidis, B. Gruenberger, T. Gruenberger, and C. Brostjan. 2013. Clinical evidence for thrombospondin-1 as a relevant suppressor of liver regeneration. Journal of hepatology 58: 1053-1054.
  • Perisanidis, C., M. Mittlbock, A. Schoppmann, G. Kornek, P. Starlinger, A. Stift, E. Selzer, C. Schopper, and R. Ewers. 2013. Postoperative failure of platelet recovery is an independent risk factor for poor survival in patients with oral and oropharyngeal cancer. Clinical oral investigations 17: 913-919.
  • Starlinger, P., L. Alidzanovic, D. Schauer, T. Maier, C. Nemeth, B. Perisanidis, D. Tamandl, B. Gruenberger, T. Gruenberger, and C. Brostjan. 2012. Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. British journal of cancer 107: 961-966.
  • Schauer, D., P. Starlinger, C. Reiter, N. Jahn, P. Zajc, E. Buchberger, T. Bachleitner-Hofmann, M. Bergmann, A. Stift, T. Gruenberger, and C. Brostjan. 2012. Intermediate monocytes but not TIE2-expressing monocytes are a sensitive diagnostic indicator for colorectal cancer. PloS one 7: e44450.
  • Hoetzenecker, K., A. Assinger, M. Lichtenauer, M. Mildner, T. Schweiger, P. Starlinger, A. Jakab, E. Berenyi, N. Pavo, M. Zimmermann, C. Gabriel, C. Plass, M. Gyongyosi, I. Volf, and H. J. Ankersmit. 2012. Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation. Basic research in cardiology 107: 292.
  • Starlinger, P., P. Brugger, D. Schauer, S. Sommerfeldt, D. Tamandl, I. Kuehrer, S. F. Schoppmann, M. Gnant, and C. Brostjan. 2011. Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment. Neoplasia (New York, N.Y.) 13: 419-427.
  • Starlinger, P., P. Brugger, C. Reiter, D. Schauer, S. Sommerfeldt, D. Tamandl, I. Kuehrer, S. F. Schoppmann, M. Gnant, and C. Brostjan. 2011. Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy. Neoplasia (New York, N.Y.) 13: 980-990.
  • Starlinger, P., L. Alidzanovic, D. Schauer, P. Brugger, S. Sommerfeldt, I. Kuehrer, S. F. Schoppmann, M. Gnant, and C. Brostjan. 2011. Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts. Dis Markers 31: 55-65.
  • Starlinger P., G. K., Gruenberger T. , Brostjan C. . 2010. Systemic effects of anti-VEGF therapy – Mini-review European Surgery Volume 42: 12-16.
  • Starlinger, P., H. P. Moll, A. Assinger, C. Nemeth, K. Hoetzenecker, B. Gruenberger, T. Gruenberger, I. Kuehrer, S. F. Schoppmann, M. Gnant, and C. Brostjan. 2010. Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. Journal of thrombosis and haemostasis : JTH 8: 1809-1819.

 

 

Reviews
  • Starlinger, P., Gebhardt, K., Gruenberger, T. and Brostjan, C. Systemic effects of anti-VEGF therapy. Eur Surg 2010. 42: 12-16.
 
Drucken
 

Schnellinfo

 
 

Featured

 
 
 
 
 
© MedUni Wien  | 
 Impressum | Nutzungsbedingungen | Datenschutzerklärung | Barrierefreiheit | Kontakt